Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Jean-Philippe Combal, Vivet CEO, will be attending a panel during the Cell & Gene Meeting on the Med - virtual, organized by the ARM on April 6-9, 2021. The panel, "TRENDS AND CHALLENGES IN GENE THERAPY IN EUROPE", will be held on April 7, 3-4pm CET.
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
Jean-Philippe Combal, Vivet Therapeutics' CEO, and Thomas Daniel, BD Director, will be hosting 1x1 meetings during Jefferies 2020 London Healthcare Conference on November 17-19.
Anne Douar, Chief Development Officer of Vivet Therapeutics, will give a presentation
VIVET ATTENDING CHARDAN'S 4th ANNUAL GENETIC MEDICINES CONFERENCE
VIVET ATTENDING THE HEALTHTECH INNOVATION DAYS (HTID) IN PARIS
Bernard Benichou Vivet Therapeutics' CMO will be participating to a panel and Jean-Philippe Combal, CEO and Sonia Valero, Head of Clinical Operations…
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease